A Comprehensive Bioinformatic Analysis of
            <i>RanBP9</i>
            Expression and Its Relation to Prognosis in Human Breast Cancer

Meng, Yiling; Ying, Ying-Xia; Zhang, Meichao; Zhang, Suning; Yuan, Yao; Dong, Li

doi:10.2217/epi-2021-0464

Cited by 4 publications

(2 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prognosis for lung carcinoma remains unfavorable, despite extensive research on innovative prognostic biomarkers across various cancer types [20][21][22][23]. The persistently poor outlook for lung cancer underscores the critical need to identify speci c biomarkers for this particular disease.…”

Section: Discussionmentioning

confidence: 99%

Low SLCO4C1 expression serves as an independent prognostic predictor in lung cancer

Wen,

Xie,

Liu

et al. 2024

Preprint

View full text Add to dashboard Cite

Lung cancer is a significant global health concern, accounting for 18.4 percent of all cancer-related deaths, imposing substantial social and economic burdens. We explored SLCO4C1 as a potential prognostic marker in lung cancer. Analyzing The Cancer Genome Atlas (TCGA) data, we assessed SLCO4C1 expression using boxplot analyses. Chi-square and Fisher's test evaluated associations with clinicopathological features, and diagnostic capacity was determined the receiver-operating characteristic (ROC) curve analysis. Kaplan-Meier survival curves assessed survival differences based on SLCO4C1 levels. Cox regression models and subgroup analyses examined prognostic factors. Our findings reveal significant downregulation of SLCO4C1 in lung cancer tissues, with correlations to patient gender, histological type, and T classification. ROC analysis indicated moderate diagnostic potential. Survival analysis demonstrated lower overall and relapse-free survival rates in patients with low SLCO4C1 expression. Univariate and multivariate Cox regression analyses suggested SLCO4C1 as an independent prognostic predictor for lung cancer. In conclusion, low SLCO4C1 expression serves as an independent prognostic biomarker in lung cancer, offering promise for prognostic and therapeutic applications.

show abstract

Section: Discussionmentioning

confidence: 99%

Low SLCO4C1 expression serves as an independent prognostic predictor in lung cancer

Wen,

Xie,

Liu

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…While the absence of RanBP9 causes perinatal lethality, occasional RanBP9-deficient mouse survivors on a mixed genetic background display reduced body size and severe sterility both in males and females 7 . Expression of RanBP9 increases in several types of malignancies 1, [8][9][10][11] . Due to the weakening of DNA repair in RanBP9deficient cells, RanBP9 has been put forward as a potential target of therapy in nonsmall cell lung cancer 9,10,12 .…”

Section: Introductionmentioning

confidence: 99%

Anin vivo“turning model” reveals new RanBP9 interactions in lung macrophages

Kajimura,

Tessari,

Orlacchio

et al. 2024

Preprint

View full text Add to dashboard Cite

The biological functions of the scaffold protein Ran Binding Protein 9 (RanBP9) remain elusive in macrophages or any other cell type where this protein is expressed together with its CTLH (C-terminal to LisH) complex partners. We have engineered a new mouse model, named RanBP9-TurnX, where RanBP9 fused to three copies of the HA tag (RanBP9-3xHA) can be turned into RanBP9-V5 tagged upon Cre-mediated recombination. We created this model to enable stringent biochemical studies at cell type specific level throughout the entire organism. Here, we have used this tool crossed with LysM-Cre transgenic mice to identify RanBP9 interactions in lung macrophages. We show that RanBP9-V5 and RanBP9-3xHA can be both co-immunoprecipitated with the known members of the CTLH complex from the same whole lung lysates. However, more than ninety percent of the proteins pulled down by RanBP9-V5 differ from those pulled-down by RanBP9-HA. The lung RanBP9-V5 associated proteome includes previously unknown interactions with macrophage-specific proteins as well as with players of the innate immune response, DNA damage response, metabolism, and mitochondrial function. This work provides the first lung specific RanBP9-associated interactome in physiological conditions and reveals that RanBP9 and the CTLH complex could be key regulators of macrophage bioenergetics and immune functions.

show abstract

Unravelling 2022: The 15th Volume of Epigenomics

Lodge

2023

Epigenomics

View full text Add to dashboard Cite

A Comprehensive Bioinformatic Analysis of RanBP9 Expression and Its Relation to Prognosis in Human Breast Cancer

Cited by 4 publications

References 46 publications

Low SLCO4C1 expression serves as an independent prognostic predictor in lung cancer

Low SLCO4C1 expression serves as an independent prognostic predictor in lung cancer

Anin vivo“turning model” reveals new RanBP9 interactions in lung macrophages

Unravelling 2022: The 15th Volume of Epigenomics

Contact Info

Product

Resources

About